Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Barclays PLC

Barclays PLC lessened its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 27.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 171,196 shares of the biotechnology company's stock after selling 66,407 shares during the period. Barclays PLC owned about 0.27% of Blueprint Medicines worth $15,836,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BPMC. Quarry LP bought a new position in Blueprint Medicines during the third quarter worth about $32,000. Covestor Ltd increased its holdings in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $108,000. CWM LLC raised its stake in Blueprint Medicines by 114.6% in the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company's stock valued at $119,000 after acquiring an additional 590 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Blueprint Medicines by 13.3% during the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $120,000 after purchasing an additional 131 shares during the last quarter.

Insider Buying and Selling at Blueprint Medicines

In related news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,079 shares of company stock valued at $937,697. Corporate insiders own 4.21% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BPMC shares. HC Wainwright restated a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. Wedbush restated an "outperform" rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Thursday, November 14th. JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Monday, December 9th. Wells Fargo & Company dropped their price target on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a report on Thursday, October 31st. Finally, UBS Group initiated coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price target for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $122.11.

Blueprint Medicines Stock Up 2.4 %

Blueprint Medicines stock traded up $2.20 during mid-day trading on Monday, reaching $95.39. The stock had a trading volume of 472,107 shares, compared to its average volume of 686,052. The company has a market capitalization of $6.06 billion, a price-to-earnings ratio of -45.21 and a beta of 0.59. Blueprint Medicines Co. has a one year low of $72.24 and a one year high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The company has a 50-day moving average price of $92.15 and a two-hundred day moving average price of $97.39.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. During the same period last year, the company earned ($2.20) EPS. The company's revenue for the quarter was up 126.5% on a year-over-year basis. On average, analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.